Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $95.2 million.

  • Ligand Pharmaceuticals' Free Cash Flow fell 64.21% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.7 million, marking a year-over-year increase of 8449.92%. This contributed to the annual value of $95.2 million for FY2024, which is 106.76% up from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Free Cash Flow is $95.2 million, which was up 106.76% from $46.1 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Free Cash Flow peaked at $119.9 million during FY2022, and registered a low of $46.1 million during FY2023.
  • In the last 3 years, Ligand Pharmaceuticals' Free Cash Flow had a median value of $95.2 million in 2024 and averaged $87.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 257.20% in 2020, then tumbled by 61.60% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Free Cash Flow (Yearly) stood at $50.1 million in 2020, then soared by 39.72% to $70.0 million in 2021, then soared by 71.23% to $119.9 million in 2022, then tumbled by 61.60% to $46.1 million in 2023, then skyrocketed by 106.76% to $95.2 million in 2024.